006620 — DongKoo Bio & Pharma Co Cashflow Statement

0.000.00%

Last trade - 00:00

HealthcareAdventurousSmall CapNeutral

Annual cashflow statement for DongKoo Bio & Pharma Co, fiscal year end - December 31st, KRW millions except per share, conversion factor applied.

	2020 December 31st	2021 December 31st	2022 December 31st	2023 December 31st	2024 December 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts	ARS	Annual Audited Accounts
Standards:	IFRS	IFRS	IFRS	IFRS	IFRS
Status:	Final	Final	Final	Final	Final
Net Income/Starting Line	9,140	9,327	6,614	11,808	1,991
Depreciation
Amortisation
Non-Cash Items	1,481	2,705	11,644	5,412	14,307
Unusual Items
Equity in Net Earnings/Losses
Other Non-Cash Items
Changes in Working Capital	-7,638	818	-7,072	-19,663	-6,228
Change in Accounts Receivable
Change in Inventories
Change in Other Assets
Change in Accounts Payable
Change in Other Liabilities
Other Operating Cash Flow
Cash from Operating Activities	7,489	17,903	16,819	3,585	17,344
Capital Expenditures	-5,461	-5,475	-11,075	-15,965	-25,465
Purchase of Fixed Assets
Purchase / Acquisition of Intangibles
Other Investing Cash Flow Items	-7,103	5,939	-15,938	10,832	-19,569
Sale of Fixed Assets
Sale/Maturity of Investment
Change in Net Investments
Purchase of Investments
Sale of Intangible Assets
Other Investing Cash Flow
Cash from Investing Activities	-12,564	464	-27,014	-5,133	-45,033
Financing Cash Flow Items	—	-76.1	-50	49	1,454
Other Financing Cash Flow
Total Cash Dividends Paid
Net Issuance / Retirement of Stock
Net Issuance / Retirement of Debt
Cash from Financing Activities	-361	-3,688	3,185	4,752	37,194
Foreign Exchange Effects
Beginning Cash Balance
Ending Cash Balance
Net Change in Cash	-5,460	14,676	-7,043	3,199	9,660